Podcasts
Pharmaceutical Executive

Pharmaceutical Executive

Pharmaceutical Executive Podcast 499 - Pharmaceutical Executive Daily: Amazon Pharmacy to Offer GLP-1 Delivery Service

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

Volume

00:00

Geen beschrijving van de aflevering beschikbaar.

Gepubliceerd 07 aug. 2026

Duur 02:55

Zoeken

Afleveringen

499-

Pharmaceutical Executive Daily: Amazon Pharmacy to Offer GLP-1 Delivery Service

Beluisterd

07 aug. 2026

498-

Pharmaceutical Executive Daily: FDA Approves Orezeyful

Beluisterd

06 aug. 2026

497-

Pharmaceutical Executive Daily: Source Denies AstraZeneca-Bristol Myers Squibb Merger Talks

Beluisterd

05 aug. 2026

496-

Pharmaceutical Executive Daily: Pathos AI Enters Two lIcensing Deals

Beluisterd

04 aug. 2026

495-

Pharmaceutical Executive Daily: AstraZeneca and Bristol Myers Squibb Held Merger Talks

Beluisterd

03 aug. 2026

494-

Pharmaceutical Executive Daily: FDA Votes 10 to 3 in Favor of Replimune's Rp1 Efficacy Data

Beluisterd

31 jul. 2026

493-

Pharmaceutical Executive Daily: Inizio Engage launches Connected Insights

Beluisterd

30 jul. 2026

492-

Pharmaceutical Executive Daily: FDA Approves Viatris's Gwyn Lo

Beluisterd

29 jul. 2026

491-

The Ron Lanton Report: The Human Bottleneck

Beluisterd

29 jul. 2026

490-

Pharmaceutical Executive Daily: BioMarin and n-Lorem Foundation Enter Collaboration

Beluisterd

28 jul. 2026

489-

Pharmaceutical Executive Daily: FDA Approves Simtriyo

Beluisterd

27 jul. 2026

488-

Pharmaceutical Executive Daily: FDA Votes to Reduce Restrictions on Four Peptides

Beluisterd

24 jul. 2026

487-

Pharmaceutical Executive Daily: Eli Lilly Reports Positive Results from Two Phase III Trials

Beluisterd

23 jul. 2026

486-

Pharmaceutical Executive Daily: Novo Nordisk Files Lawsuit Against Eli Lilly

Beluisterd

22 jul. 2026

485-

Pharmaceutical Executive Daily: FDA Grants Emergency Use Authorization to Allplex Assay

Beluisterd

21 jul. 2026

484-

Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia

Beluisterd

20 jul. 2026

483-

Pharmaceutical Executive Daily: FDA Grants Traditional Approval to Novartis's Fabhalta

Beluisterd

17 jul. 2026

482-

Pharmaceutical Executive Daily: FDA Approves Lipfendra

Beluisterd

16 jul. 2026

481-

Hiring and Fostering Top Talent

Beluisterd

16 jul. 2026

480-

The Power of Better Questions: How Great Leaders Balance Risk, Growth and Curiosity

Beluisterd

16 jul. 2026

479-

Pharmaceutical Executive Daily: FDA Approves Reytorpyk for Advanced Breast Cancer

Beluisterd

15 jul. 2026

478-

Pharmaceutical Executive Daily: FDA Approves Subcutaneous Formulation of Leqembi Iqlik

Beluisterd

14 jul. 2026

477-

Pharmaceutical Executive Daily: FDA Issues CRL to Elevar Therapeutics

Beluisterd

13 jul. 2026

476-

Pharmaceutical Executive Daily: FDA Approves Subcutaneous Sarclisa Escena

Beluisterd

10 jul. 2026

475-

Pharmaceutical Executive Daily: FDA Approves Ennumo

Beluisterd

09 jul. 2026

474-

Pharmaceutical Executive Daily: AI as Reinvention

Beluisterd

08 jul. 2026

473-

“AI as Reinvention”: Transforming the Business of Medicine

Beluisterd

08 jul. 2026

472-

Pharmaceutical Executive Daily: The Changing Reality of Pharmaceutical Commercialization

Beluisterd

07 jul. 2026

471-

Pharmaceutical Executive Daily: The Medicare GLP-1 Bridge

Beluisterd

01 jul. 2026

470-

Pharmaceutical Executive Daily: FDA Names Seven Participants to Precheck Program

Beluisterd

30 jun. 2026

469-

Pharmaceutical Executive Daily: Ipsen Enters Merger Agreement to Acquire Kartos Therapeutics

Beluisterd

29 jun. 2026

468-

Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

Beluisterd

25 jun. 2026

467-

Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration

Beluisterd

24 jun. 2026

466-

Pharmaceutical Executive Daily: FDA Pilot Targets Faster Early-Stage Drug Trial Starts

Beluisterd

23 jun. 2026

465-

Pharmaceutical Executive Daily: AbbVie Acquires Apogee Therapeutics for $10.9 Billion

Beluisterd

22 jun. 2026

464-

Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010

Beluisterd

19 jun. 2026

463-

Pharmaceutical Executive Daily: FDA Approves Utebzi and Capvaxive

Beluisterd

18 jun. 2026

462-

Pharmaceutical Executive Daily: Meaningfully Improving Therapy Persistence in Patient Support Programs

Beluisterd

17 jun. 2026

461-

Pharmaceutical Executive Daily: FDA has Approved Skinvive by Juvéderm

Beluisterd

16 jun. 2026

460-

Pharmaceutical Executive Daily: FDA Approves Two Indications of Keytruda in Combination with Welireg

Beluisterd

15 jun. 2026

459-

Pharmaceutical Executive Daily: Kardigan Sets Terms for $350 Million IPO

Beluisterd

12 jun. 2026

458-

Pharmaceutical Executive Daily: China's Latest Policy Guidance

Beluisterd

11 jun. 2026

457-

Pharmaceutical Executive Daily: Parabilis Medicines Prices Record-Breaking $670 Million IPO

Beluisterd

10 jun. 2026

456-

The Ron Lanton Report: From Innovation to Infrastructure

Beluisterd

10 jun. 2026

455-

Pharmaceutical Executive Daily: GSK Acquires Nuvalent for $10.6 Billion

Beluisterd

09 jun. 2026

454-

Pharmaceutical Executive Daily: Roche and Nurix Therapeutics Announce Global Collaboration

Beluisterd

08 jun. 2026

453-

Pharmaceutical Executive Daily: Supreme Court Unanimously Rules in Favor of Hikma Pharmaceuticals in Skinny Label Case

Beluisterd

05 jun. 2026

452-

Pharmaceutical Executive Daily: Alnylam Pharmaceuticals and Inceptive Nucleics Announce 3 Year Strategic Collaboration

Beluisterd

04 jun. 2026

451-

Navigating PBM Pitfalls: Protecting Revenue in a Complex Rebate Landscape

Beluisterd

04 jun. 2026

450-

Pharmaceutical Executive Daily: New FDA Draft Guidance Targets Gene Therapy Submission Burden

Beluisterd

03 jun. 2026